ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

High-risk rhabdomyosarcoma (RMS) occurring in childhood to young adulthood is associated with a poor prognosis; especially children above the age of 10 with advanced stage alveolar RMS still succumb to the disease within a median of 2 years. The advent of chimeric antigen receptor (CAR)-engineered T...

Full description

Bibliographic Details
Main Authors: Michael Merker, Juliane Wagner, Hermann Kreyenberg, Catrin Heim, Laura M. Moser, Winfried S. Wels, Halvard Bonig, Zoltán Ivics, Evelyn Ullrich, Thomas Klingebiel, Peter Bader, Eva Rettinger
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
cellular therapy
cytokine-induced killer cells
chimeric antigen receptor
rhabdomyosarcoma
ERBB2 (HER2/neu)
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.581468/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.581468/full

Similar Items